Cargando…

Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients

BACKGROUND: Histologically, node-negative breast cancer generally have a good prognosis. However, 10 to 30% of the cases present local relapses or metastasis. This group of people has high chances of remission if detected early. The aim of this study is to identify financial affordability for develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zemni, Ines, Ghalleb, Montassar, Jbir, Ichraf, Slimane, Maher, Ben Hassouna, Jamel, Ben Dhieb, Tarek, Bouzaiene, Hatem, Rahal, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701354/
https://www.ncbi.nlm.nih.gov/pubmed/29169398
http://dx.doi.org/10.1186/s12957-017-1272-7
_version_ 1783281319148519424
author Zemni, Ines
Ghalleb, Montassar
Jbir, Ichraf
Slimane, Maher
Ben Hassouna, Jamel
Ben Dhieb, Tarek
Bouzaiene, Hatem
Rahal, Khaled
author_facet Zemni, Ines
Ghalleb, Montassar
Jbir, Ichraf
Slimane, Maher
Ben Hassouna, Jamel
Ben Dhieb, Tarek
Bouzaiene, Hatem
Rahal, Khaled
author_sort Zemni, Ines
collection PubMed
description BACKGROUND: Histologically, node-negative breast cancer generally have a good prognosis. However, 10 to 30% of the cases present local relapses or metastasis. This group of people has high chances of remission if detected early. The aim of this study is to identify financial affordability for developing countries to adjust treatment. METHODS: We selected 405 patients with histologically confirmed node-negative breast cancer in our institution between January 2001 and December 2003. Patients with metastasis were excluded. The statistical analysis was conducted using SPSS ver. 18 (SPSS, Inc., Chicago, Illinois). RESULTS: The medial age was 51 years old. The medial tumor size was 35.4 mm. Clinically, 67.2% of the patients were staged cT2 and 63.2%, cN1i. Breast conservation was achieved in 41% of cases. In the histologic examination, the medial size was 30 mm. Grade III tumors were found in 50.1% of patients and positive hormonal receptors in 53.4%. The mean number of lymph nodes was 14. Eight patients had neoadjuvant chemotherapy. Adjuvant locoregional radiation and adjuvant chemotherapy were prescribed respectively in 70.6 and 64.4% of cases. 59.7% had adjuvant hormonal therapy. The follow-up showed 17.7% cases of relapse either locally or in a metastatic way in a mean time of 57.4 months. The disease-free survival at 5 years was 82.1%, and the overall survival for the same period was 91.5%. The histologic tumor size and the grade and number of lymph node dissected were shown to be influencing the disease-free survival. Radiation therapy and hormone therapy showed improved disease-free survival and overall survival. CONCLUSION: Our study found interesting results that may help personalize the treatment especially for patient living in underdeveloped countries, but further studies are needed to evaluate those and more accessible prognostic factors for a more accessible healthcare.
format Online
Article
Text
id pubmed-5701354
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57013542017-12-01 Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients Zemni, Ines Ghalleb, Montassar Jbir, Ichraf Slimane, Maher Ben Hassouna, Jamel Ben Dhieb, Tarek Bouzaiene, Hatem Rahal, Khaled World J Surg Oncol Research BACKGROUND: Histologically, node-negative breast cancer generally have a good prognosis. However, 10 to 30% of the cases present local relapses or metastasis. This group of people has high chances of remission if detected early. The aim of this study is to identify financial affordability for developing countries to adjust treatment. METHODS: We selected 405 patients with histologically confirmed node-negative breast cancer in our institution between January 2001 and December 2003. Patients with metastasis were excluded. The statistical analysis was conducted using SPSS ver. 18 (SPSS, Inc., Chicago, Illinois). RESULTS: The medial age was 51 years old. The medial tumor size was 35.4 mm. Clinically, 67.2% of the patients were staged cT2 and 63.2%, cN1i. Breast conservation was achieved in 41% of cases. In the histologic examination, the medial size was 30 mm. Grade III tumors were found in 50.1% of patients and positive hormonal receptors in 53.4%. The mean number of lymph nodes was 14. Eight patients had neoadjuvant chemotherapy. Adjuvant locoregional radiation and adjuvant chemotherapy were prescribed respectively in 70.6 and 64.4% of cases. 59.7% had adjuvant hormonal therapy. The follow-up showed 17.7% cases of relapse either locally or in a metastatic way in a mean time of 57.4 months. The disease-free survival at 5 years was 82.1%, and the overall survival for the same period was 91.5%. The histologic tumor size and the grade and number of lymph node dissected were shown to be influencing the disease-free survival. Radiation therapy and hormone therapy showed improved disease-free survival and overall survival. CONCLUSION: Our study found interesting results that may help personalize the treatment especially for patient living in underdeveloped countries, but further studies are needed to evaluate those and more accessible prognostic factors for a more accessible healthcare. BioMed Central 2017-11-23 /pmc/articles/PMC5701354/ /pubmed/29169398 http://dx.doi.org/10.1186/s12957-017-1272-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zemni, Ines
Ghalleb, Montassar
Jbir, Ichraf
Slimane, Maher
Ben Hassouna, Jamel
Ben Dhieb, Tarek
Bouzaiene, Hatem
Rahal, Khaled
Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
title Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
title_full Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
title_fullStr Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
title_full_unstemmed Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
title_short Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
title_sort identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701354/
https://www.ncbi.nlm.nih.gov/pubmed/29169398
http://dx.doi.org/10.1186/s12957-017-1272-7
work_keys_str_mv AT zemniines identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT ghallebmontassar identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT jbirichraf identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT slimanemaher identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT benhassounajamel identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT bendhiebtarek identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT bouzaienehatem identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients
AT rahalkhaled identifyingaccessibleprognosticfactorsforbreastcancerrelapseacasestudyon405histologicallyconfirmednodenegativepatients